EO 14401 directs FDA and DEA to create Right to Try pathways for Schedule I psychedelic drugs including ibogaine, leverages existing FDA Breakthrough Therapy designation mechanisms for qualifying psychedelics, allocates funds from existing HHS and ARPA-H budgets to federal-state psychedelic research partnerships, and orders the Attorney General to initiate expedited rescheduling review for any Schedule I substance that successfully completes clinical trials. Specific dollar figures and any named voucher instruments cited beyond what the source excerpt confirms should be treated as unverified pending full EO text review.
The record
Healthcare
1 shown · filtered. Every entry signed by a specialist, linked to its source, and citable by paragraph.